Programs & products

Updated clinical data show preliminary anti-tumor activity in patients with recurrent/metastatic microsatellite -stable colorectal cancer (MSS-CRC ), a population historically unresponsive to PD-1/L1...

Preliminary activity observed in patients with recurrent/metastatic microsatellite -stable colorectal cancer (MSS-CRC ), a population historically unresponsive to PD-1/L1 blockade 3 partial responses...

Cash, cash equivalents and financial assets of the Company amounted to €153.8 million* Significant momentum across the portfolio, with good progress on the joint monalizumab program with AstraZeneca...

8 partial responses (PR) among 26 patients evaluable for efficacy – predefined number of responses needed to declare the trial result positive has been reached The combination was well tolerated...

Next generation of immunotherapies presented by Chief Scientific Officer Eric Vivier in a meet-the-expert session at AACR 2018 New preclinical data further support ongoing clinical trials with...

Additional expansion cohorts to explore the safety and efficacy of monalizumab in combination with durvalumab and standard of care in patients with 1 st - and 2 nd line, metastatic colorectal cancer...

First clinical activity data of the combination of monalizumab and cetuximab New preclinical data further supporting the rationale of Innate’s first- or best-in-class antibodies Eric Vivier, Chief...

Innate Pharma presents a clinical update on its broad and diverse development portfolio of first- or best-in-class antibodies in immuno-oncology Update on the development program with AstraZeneca on...

Lirilumab continues to be well-tolerated in monotherapy and in combination across multiple tumor indications in an exploratory clinical program with partner Bristol-Myers Squibb The combination of...

Cash, cash equivalents and financial assets* for the Company amounted to €204.1m (million euros) as of June 30, 2017 Significant clinical progress within the period: Dose-escalation data of the...